Every 10-Q that SELECTIS HEALTH INC (GBCS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GBCS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GBCS filings page.
Selectis Health, Inc. (GBCS) reported Q2 2026 results showing a sharp shift driven by asset sales and balance sheet repair. For the three months ended June 30, 2026, healthcare revenue fell to $4.6 million from $10.4 million, mainly due to selling four Georgia facilities. Despite lower operating scale, a $10.2 million gain on the May sale of two Georgia facilities and prior January sales produced net income of $8.1 million for the quarter and $14.6 million for the first half, versus losses in 2025. Basic EPS was $2.65 for the quarter and $4.77 year-to-date.
Total debt (net of discount) decreased to $17.0 million from $31.0 million, and stockholders’ position moved from a $(6.6) million deficit at December 31, 2025 to positive equity of $8.0 million at June 30, 2026, supported by asset sale gains and debt paydowns. Cash, cash equivalents and restricted cash increased to $7.9 million, aided by $28.9 million of Georgia sale proceeds, but operating cash flow was negative $4.3 million for the first half.
Management states that substantial doubt exists about the company’s ability to continue as a going concern due to historical losses and projected cash needs. The company discloses continuing material weaknesses in internal control over financial reporting. On June 22, 2026, Selectis entered into a Merger Agreement under which a subsidiary of Black Pearl Equities II, LLC will launch a cash tender offer to acquire all outstanding common shares at $5.75 per share, subject to a 70% minimum tender and other conditions, followed by a cash merger.
Selectis Health, Inc. reported a sharp swing to profitability for the three months ended March 31, 2026, driven by asset sales rather than core operations. The company generated net income of $6,526,382, or $2.13 basic and $1.90 diluted earnings per share, compared with a net loss of $655,969 a year earlier.
Total revenue fell to $7,288,602 from $10,486,939, a 32% decline, mainly because two Georgia facilities were sold in January 2026. Healthcare revenue dropped to $7,181,161, partly offset by new management fee revenue of $107,441. Operations posted a loss from operations of $1,262,493, but the company recognized a gain on sale of assets of $8,896,309 from the January sale of two Georgia facilities for gross proceeds of $13.2 million.
Asset sales and debt repayment significantly reshaped the balance sheet. Total debt, net of discounts, declined to $22,388,505 from $31,000,562, and total liabilities fell to $29,753,846 from $38,788,531. Stockholders’ equity improved from a deficit of $(6,210,538) at December 31, 2025 to positive equity of $258,344 at March 31, 2026.
Despite these improvements, liquidity remains strained. Cash and cash equivalents were $1,286,452 and restricted cash $192,129, and the company reported negative working capital of about $6.5 million and an accumulated deficit of $14,726,006. Management concluded that substantial doubt exists about Selectis Health’s ability to continue as a going concern and outlined plans to increase occupancy and reimbursement, sell additional facilities, control costs, and seek new capital.
The company continued to reposition its portfolio. As of March 31, 2026 it owned ten long-term care facilities with 712 operating beds and 141 leased beds, primarily in Arkansas, Ohio and Oklahoma, and had completed or agreed to sell all four Georgia skilled nursing facilities for combined gross proceeds of $28.9 million. Management also disclosed a material weakness in disclosure controls and procedures and plans to implement multi-level review and work with third parties to strengthen internal controls.
Selectis Health, Inc. (GBCS) reported Q3 2025 results showing healthcare revenue of $10,839,954 versus $10,016,416 a year ago, driven by higher Medicaid rates in Georgia and Oklahoma. Net income was $752,365 compared to a prior-year loss, aided by $659,923 from employee retention credits and higher other income.
For the nine months, the company recorded a net loss of $211,631 versus $1,847,498 last year, with interest expense lower on reduced debt. Liquidity remains tight: cash was $417,125 and restricted cash $806,886 as of September 30, 2025, with a working capital deficit of approximately $16.3 million. Total debt, net of discount, was $31,126,545, and the company disclosed noncompliance with two loan covenants, classifying related amounts as current. Management noted substantial doubt about continuing as a going concern and outlined plans to increase occupancy and rates, control costs, and seek capital. As of November 12, 2025, common shares outstanding were 3,067,059.